Theodorakopoulou Marieta, Ortiz Alberto, Fernandez-Fernandez Beatriz, Kanbay Mehmet, Minutolo Roberto, Sarafidis Pantelis A
First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
Clin Kidney J. 2024 Nov 22;17(Suppl 2):36-50. doi: 10.1093/ckj/sfae278. eCollection 2024 Dec.
Until recently, major bodies producing guidelines for the management of hypertension in patients with chronic kidney disease (CKD) disagreed in some key issues. In June 2023, the European Society of Hypertension (ESH) published the new 2023 ESH Guidelines for the management of arterial hypertension a document that was endorsed by the European Renal Association. Several novel recommendations relevant to the management of hypertension in patients with CKD appeared in these guidelines, which have been updated to reflect the latest evidence-based practices in managing hypertension in CKD patients. Most of these are in general agreement with the previous 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines-some reflect different emphasis on some topics (i.e. detailed algorithms on antihypertensive agent use) while others reflect evolution of important evidence in recent years. The aim of the present review is to summarize and comment on key points and main areas of focus in patients with CKD, as well as to compare and highlight the main differences with the 2021 KDIGO Guidelines for the management of blood pressure in CKD.
直到最近，为慢性肾脏病（CKD）患者制定高血压管理指南的主要机构在一些关键问题上仍存在分歧。2023年6月，欧洲高血压学会（ESH）发布了新的《2023年ESH动脉高血压管理指南》，该文件得到了欧洲肾脏协会的认可。这些指南中出现了一些与CKD患者高血压管理相关的新建议，这些建议已经更新，以反映CKD患者高血压管理中最新的循证实践。其中大多数与之前的《2021年改善全球肾脏病预后（KDIGO）指南》基本一致——有些反映了对某些主题的不同侧重点（即抗高血压药物使用的详细算法），而另一些则反映了近年来重要证据的演变。本综述的目的是总结和评论CKD患者的关键点和主要关注领域，并比较和突出与《2021年KDIGO CKD血压管理指南》的主要差异。
